Tecnimede

Tecnimede

Sintra, Portugal· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $30M

Overview

Tecnimede is a well-established, private Portuguese pharmaceutical player with a core business in generic drugs. It has built integrated capabilities spanning development, manufacturing, and marketing, primarily serving the Iberian and international markets. The company's strategy involves leveraging its generic foundation to support a growing portfolio of value-added medicines and innovative healthcare solutions. Its longevity and vertical integration position it as a significant contributor to pharmaceutical access in its operating regions.

MultipleGenerics

Technology Platform

Integrated pharmaceutical development and manufacturing platform focused on generic drug formulation, bioequivalence, and GMP production, with capabilities extending to innovative drug delivery and value-added medicines.

Funding History

1
Total raised:$30M
Debt$30M

Opportunities

Growth in generic drug demand driven by global healthcare cost containment and patent expirations.
Expansion into emerging markets in Africa and Latin America presents significant volume opportunities.
Developing value-added innovative products allows for margin improvement and portfolio differentiation.

Risk Factors

Intense price competition and regulatory pressure leading to generic drug price erosion.
Regulatory delays or failures in bioequivalence studies for new generic approvals.
Supply chain vulnerability and API cost volatility impacting manufacturing margins.

Competitive Landscape

Operates in the highly competitive global generic pharmaceutical sector, competing with large multinational generics firms (e.g., Teva, Sandoz) and regional players. In Portugal and Spain, it faces competition from other Iberian generics manufacturers and subsidiaries of international groups. Differentiation is sought through integrated operations, niche products, and innovative formulations.